{"DataElement":{"publicId":"58228","version":"3","preferredName":"Cancer Prior Treatment Ind-3","preferredDefinition":"the yes/no/unknown indicator to specify if the patient previously took any kind of treatment.","longName":"CA_PRIOR_TX_IND3","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2189816","version":"1","preferredName":"Cancer Prior Treatment","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"CA_PRIOR_TX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2186369","version":"1","preferredName":"Malignant Neoplasm","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0647F5B-A888-4B87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-03","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2736850","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4942A454-EC66-4C3B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-03-25","modifiedBy":"ONEDATA","dateModified":"2008-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64054FE-E5E0-408F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-01-30","changeDescription":null,"administrativeNotes":"2023.1.30 Per GD, replaced retired concept C15368 with concept C49236, no version needed. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506034","version":"1","preferredName":"Yes No Unknown Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"YES_NO_UNKNOWN_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D05-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D0F-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D1A-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2548260","version":"1","preferredName":"Ind-3","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"C38148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Unknown Response","conceptCode":"C38148","definition":"A response or indicator that can have a value of yes, no, or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"23801A33-5B13-534B-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2006-11-30","endDate":"2016-04-27","createdBy":"BIRNBAUA","dateCreated":"2006-11-30","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 4-27-2016 per Tina Taylor approved by Dianne Reeves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C379D9D0-6CF1-CCDD-E040-BB89AD432590","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TITARENI","dateModified":"2021-09-14","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 3/35/2016 jk removed \"indeterminate\" value that was added in error. 7/7/2021wz: added ALT VM name for HOPE-CARE project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811949","version":"1","longName":"Brain","context":"CTEP"},{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"10000607","version":"1","longName":"Sarcoma","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"},{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811959","version":"1","longName":"Patient Char.","context":"CTEP"},{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"},{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"},{"publicId":"2811885","version":"1","longName":"Adult STS Recurrent","context":"CTEP"},{"publicId":"2811889","version":"1","longName":"Ped STS Recurrent","context":"CTEP"},{"publicId":"10000028","version":"1","longName":"Bone Sarcoma Recur","context":"CTEP"},{"publicId":"2811904","version":"1","longName":"Multiple Myeloma","context":"CTEP"},{"publicId":"2811905","version":"1","longName":"Primary Amyloidosis","context":"CTEP"},{"publicId":"2811906","version":"1","longName":"Waldenstrom Macrogl","context":"CTEP"},{"publicId":"2812014","version":"1","longName":"Primary Brain Recurr","context":"CTEP"},{"publicId":"2812015","version":"1","longName":"Metastatic Brain","context":"CTEP"},{"publicId":"10000462","version":"1","longName":"Muscle Invasive Blad","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280818","version":"1","longName":"UWI2014-03-01","context":"DCP"}]},{"publicId":"6147165","version":"1","longName":"Wake Forest Baptist Medical Center","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6147167","version":"1","longName":"WFB","context":"NCIP"}]}],"AlternateNames":[{"name":"CA_PRIOR_TX_IND-3","type":"USED_BY","context":"CTEP"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"20058590058228","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"CA_PRIOR_TX_IND3","type":"USED_BY","context":"CTEP"},{"name":"CA_PRIOR_TX_IND3","type":"USED_BY","context":"COG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"CA_PRIOR_TX_IND3","type":"USED_BY","context":"CITN"},{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"CANCER_PRIOR_TX_IND","type":"COG GDE Short Name","context":"COG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PTTXALLAML","type":"COG GDE Short Name","context":"COG"},{"name":"IE_IEORRES_RECTAL","type":"OID, CCTG","context":"CCTG"},{"name":"PRIOR_ANTI_TX","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Prior treatment for this cancer","url":null,"context":"CTEP"},{"name":"Prior Treatment","type":"Preferred Question Text","description":"Prior Treatment","url":null,"context":"CTEP"},{"name":"1-COMMENT","type":"COMMENT","description":"Add instruction: If yes, respond to treatment-specific questions below.","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Patients must not have had treatment given for this breast cancer prior to study entry","url":null,"context":"CTEP"},{"name":"9177 prior treatment","type":"Alternate Question Text","description":"Has had no prior treatment except local radiation or short course steroids for acute symptoms","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"Did the patient have treatment including RT, chemotherapy, targeted therapy, or endocrine therapy for the currently dignosed breast cancer prior to randomization","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Was this treatment started prior to the first dose of study medication","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"No prior radiation, chemotherapy, or biologics.","url":null,"context":"CTEP"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Tolerability to prior treatment","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Indicate \"Yes\" or \"No\" for all prior cancer treatments the patient has received","url":null,"context":"ECOG-ACRIN"},{"name":"CITN","type":"Alternate Question Text","description":"Prior therapy requirements: No prior radiation, chemotherapy or biologics.","url":null,"context":"CITN"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Prior Treatment:","url":null,"context":"CTEP"},{"name":"COG_CRF_Text_1","type":"Alternate Question Text","description":"Has patient completed cancer treatment greater than or equal to 2 years prior to study enrollment?","url":null,"context":"CTEP"},{"name":"CITN Text 1","type":"Alternate Question Text","description":"Did patient receive any prior drug therapy for this disease?","url":null,"context":"CITN"},{"name":"CITN Text 2","type":"Alternate Question Text","description":"Did patient receive any prior radiation therapy for this disease?","url":null,"context":"CITN"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Prior therapy","url":null,"context":"Alliance"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has patient been treated for high-risk neuroblastoma?","url":null,"context":"COG"},{"name":"CRF TEXT7","type":"Alternate Question Text","description":"Prior cancer treatment (ablation/HIFU/cryo) to prostate gland","url":null,"context":"NRG"},{"name":"DCP Text 1","type":"Alternate Question Text","description":"Prior radiation therapy","url":null,"context":"DCP"},{"name":"NRG CRF_Text","type":"Alternate Question Text","description":"Treated?","url":null,"context":"NRG"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Has patient received prior cisplatin or carboplatin based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor?","url":null,"context":"COG"},{"name":"NRG CRF TEXT 8","type":"Alternate Question Text","description":"Prior whole gland ablative therapy (ablation/HIFU/cryo) to prostate gland","url":null,"context":"NRG"},{"name":"COG CRF TEXT 8","type":"Alternate Question Text","description":"Has patient received any prior drug therapy for this disease?","url":null,"context":"COG"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Prior radionuclide therapy?","url":null,"context":"Alliance"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Prior liver-directed or other ablative therapy?","url":null,"context":"Alliance"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Did the patient have one prior chemotherapeutic regimen for management of endometrial carcinoma?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient been previously treated for brain metastases?","url":null,"context":"NRG"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Prior therapy to control disease complications for this cancer","url":null,"context":"Alliance"},{"name":"CRF Text12","type":"Alternate Question Text","description":"Has the patient received prior treatment for this cancer?","url":null,"context":"Alliance"},{"name":"Prior TX","type":"Alternate Question Text","description":"Patient has received therapy for any other cancer within last 3 years (except for non-melanoma skin cancer).","url":null,"context":"NCIP"},{"name":"CRF Text13","type":"Alternate Question Text","description":"Prior cancer therapy?","url":null,"context":"Alliance"},{"name":"CRF Text14","type":"Alternate Question Text","description":"Prior treated brain metastases?","url":null,"context":"Alliance"},{"name":"NRG_CRF_Text9","type":"Alternate Question Text","description":"Prior intraplueral therapy","url":null,"context":"NRG"},{"name":"NRG_CRF_Text 10","type":"Alternate Question Text","description":"Has the patient ever received chemotherapy or radiation therapy for the study cancer?","url":null,"context":"NRG"},{"name":"CRF Text 15","type":"Alternate Question Text","description":"Did the patient have any prior therapy for glioblastoma (GBM) except for biopsy or resection?","url":null,"context":"NRG"},{"name":"COG CRF Text 16","type":"Alternate Question Text","description":"Has patient received prior therapy with a CD123 directed antibody or CD123 directed CAR T cells?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Has the patient had any prior therapy for endometrial cancer, including hormonal therapy, chemotherapy, targeted therapy, immunotherapy or radiation therapy?","url":null,"context":"NRG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Did patient's curative cancer treatment include chemotherapy and/or radiation?","url":null,"context":"COG"},{"name":"NRG CRF_Text 12","type":"Alternate Question Text","description":"Has the patient received neoadjuvant (induction) and/or adjuvant chemotherapy for primary NPC with chemotherapy at or within 6 months prior to registration?","url":null,"context":"NRG"},{"name":"COG CRF Text 17","type":"Alternate Question Text","description":"Has patients received prior therapy with a CD123-targeting agent?","url":null,"context":"COG"},{"name":"CRF Text16","type":"Alternate Question Text","description":"Prior Liver-directed or Other Ablative Treatment","url":null,"context":"Alliance"},{"name":"CRF Text 18","type":"Alternate Question Text","description":"Did the patient receive at least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy?","url":null,"context":"NRG"},{"name":"CRF Text 19","type":"Alternate Question Text","description":"Did the patient have any prior therapy for glioblastoma (GBM) except for surgical resection?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Has the patient had any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy administered for the currently diagnosed breast cancer prior to study entry?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_11","type":"Alternate Question Text","description":"Has the patient had a prior curative attempt to treat the prostate?","url":null,"context":"NRG"},{"name":"CRF Text21","type":"Alternate Question Text","description":"Prior systemic therapy or radiation therapy for T-Cell lymphoma?","url":null,"context":"Alliance"},{"name":"DCP-Text-2","type":"Alternate Question Text","description":"Has participant received systemic adjuvant or neo-adjuvant therapy for breast cancer?","url":null,"context":"DCP"},{"name":"CRF Text20","type":"Alternate Question Text","description":"Prior therapy?","url":null,"context":"Alliance"},{"name":"COG CRF Text 18","type":"Alternate Question Text","description":"Has patient received prior treatment with dasatinib, or any TKI other than Imatinib?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Has the patient had any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy administered for the currently diagnosed breast cancer prior to study entry, other than short course endocrine therapy of less than 6 weeks duration post core biopsy and pre surgery?","url":null,"context":"NRG"},{"name":"NRG CRF_Text 13","type":"Alternate Question Text","description":"Did the patient receive pre-study neoadjuvant therapy","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_14","type":"Alternate Question Text","description":"Has the patient had prior hormonal therapies, immunotherapy, or antiangiogenic therapies?","url":null,"context":"NRG"},{"name":"CRF Text 22","type":"Alternate Question Text","description":"Prior systemic cancer therapy?","url":null,"context":"Alliance"},{"name":"CRF Text 23","type":"Alternate Question Text","description":"Prior anti-cancer treatment?","url":null,"context":"CCTG"},{"name":"CRF Text 24","type":"Alternate Question Text","description":"Prior anti-cancer treatment completed greater than or equal to 28 days prior to registration? (Except palliative radiation)","url":null,"context":"Alliance"},{"name":"CRF text 25","type":"Alternate Question Text","description":"Prior anti-cancer treatment completed >= 14 days prior to registration?","url":null,"context":"Alliance"},{"name":"COG CRF Text 19","type":"Alternate Question Text","description":"Has the patient received previous systemic therapy for osteosarcoma or a prior oncologic diagnosis?","url":null,"context":"COG"},{"name":"NRG_CRF_Text_15","type":"Alternate Question Text","description":"Has the patient received neoadjuvant or adjuvant chemotherapy or radiotherapy for the treatment of this disease?","url":null,"context":"NRG"},{"name":"NRG CRF_Text_2","type":"Alternate Question Text","description":"Has the patient received prior therapy?","url":null,"context":"NRG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Has patient received prior treatment with dasatinib, nilotinib, ponatinib or any TKI other than Imatinib?","url":null,"context":"COG"},{"name":"Alliance - 1","type":"Alternate Question Text","description":"Prior cancer-directed therapy?","url":null,"context":"Alliance"},{"name":"COG CRF Text 20","type":"Alternate Question Text","description":"Has patient been treated for ALL or AML?","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Has patient completed all cancer treatment (oral or intravenous) at least 36 months prior to enrollment?","url":null,"context":"COG"},{"name":"Alliance - 2","type":"Alternate Question Text","description":"Prior systemic anti-cancer therapy?","url":null,"context":"Alliance"},{"name":"ECOG-ACRIN - 1","type":"Alternate Question Text","description":"Has the patient had any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation or experimental therapy?","url":null,"context":"ECOG-ACRIN"},{"name":"NRG Text 15","type":"Alternate Question Text","description":"Prior therapy for glioblastoma (GBM) except for surgical resection or Laser Interstitial Thermal Therapy","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Has the patient had any treatment with radiation therapy, chemotherapy, or biotherapy administered for the currently diagnosed breast cancer prior to pre-entry?","url":null,"context":"NRG"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Has patient received prior treatment with dasatinib, nilotinib, ponatinib or any TKI other than dasatinib?","url":null,"context":"COG"},{"name":"COG CRF Text 21","type":"Alternate Question Text","description":"Has patient received prior treatment with any TKI other than dasatinib?","url":null,"context":"COG"},{"name":"ECOG-ACRIN - 2","type":"Alternate Question Text","description":"Has the patient been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, Ribociclib or Kisqali and Abemaciclib or Verzenio?","url":null,"context":"ECOG-ACRIN"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Prior treatment for rectal cancer.","url":null,"context":"CCTG"},{"name":"NRG_eCRF_Text_15","type":"Alternate Question Text","description":"Has the patient had any treatment with radiation therapy, chemotherapy, or biotherapy administered for the currently diagnosed breast cancer prior to study pre-entry/Step 1?","url":null,"context":"NRG"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"Did patient have prior anti-cancer therapy?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B2151548-2558-1A87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"KUMMEROA","dateModified":"2024-01-04","changeDescription":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":"2024.1.4 AQT/Alt SN added per ticket request CADSR-TASK0003337. ak 11.09.2023 Added AQT per request ticketCADSR0003062_mmt  \r\n9/27/23 Added AQT per ticket number CADSR0002884 cjl. 2023.6.29 AQT added per ticket request CADSR0002564. ak 1/20/2023: Added AQT per cadsr0002069.wz","unresolvedIssues":null,"deletedIndicator":"No"}}